What are your top takeaways in GI Cancers from ESMO 2024?

1. Re: the IMbrave050 trial: It was perhaps not unexpected, but still disappointing, to see the trial did not meet its primary endpoint of improvement in RFS. It would be interesting to see if there is a signal in preventing late recurrences, as we know there are two groups of patients: those that rec...

Here’s one that led to an immediate change in my clinic – the benefit of adding PD1 immunotherapy to front-line chemo for metastatic anal cancer showing improvement in PFS and OS:

https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/show/session/101

[The POD1UM trial, title LBA2 - POD1UM-303/In...